Document Type : Original Article(s)


1 Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

3 General Practitioner, Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran


BACKGROUND: We investigated clinical and procedural factors associated with the no-reflow phenomenon following percutaneous coronary intervention (PCI) of the saphenous-vein grafts (SVG). METHODS: A cross-sectional study was done on patients who had undergone PCI of the SVG. Patients’ medical documents were reviewed for demographic, clinical, laboratory, and procedural data. Slow/no-reflow was defined based on the thrombolysis in myocardial infarction (TIMI) grade (0 to 2). Univariate and multiple logistic regression analyses were performed to investigate factors associated with slow/no-reflow and P < 0.050 was considered as significant. RESULTS: A total of 205 patients were studied (81% man, mean ± standard deviation of age was 66.8 ± 9.6 years). Slow/no-reflow was found in 38 (18.5%) patients. High diastolic blood pressure (P = 0.010), leukocytosis (P = 0.017), diffuse lesions (P = 0.007), degenerated SVG (P < 0.001), proximal lesions (P < 0.001), thrombosis (P = 0.013), and lower number of used stents during procedure (P = 0.032) were associated with slow/no-reflow in unadjusted analyses. Factors independently associated with slow/no-reflow were pre-procedural high diastolic blood pressure with odds ratio (OR) = 3.858 [95% confidence interval (95% CI), 1.157-12.860], degenerated SVG with OR = 5.901 (95% CI: 1.883-18.492), proximal lesions with OR = 5.070 (95% CI: 1.822-14.113), pre-intervention TIMI grade with OR = 0.618 (95% CI: 0.405-0.942), number of used stents for PCI with OR = 0.074 (95% CI: 0.011-0.481) for > 1 stent, and length of stents used for PCI with OR = 0.100 (95% CI: 0.019-0.529) for > 30 mm stents. CONCLUSION: This study on the clinical and procedural factors associated with the slow/no-reflow phenomenon following PCI of the SVG can be used in risk estimation of this serious complication and tailoring preventive strategies to at-risk patients.   


  1. Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124(23): e652-e735.
  2. Sipahi I, Akay MH, Dagdelen S, Blitz A, Alhan C. Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: Meta-analysis of randomized clinical trials of the arterial grafting and stenting era. JAMA Intern Med 2014; 174(2): 223-30.
  3. Harskamp RE, Lopes RD, Baisden CE, de Winter RJ, Alexander JH. Saphenous vein graft failure after coronary artery bypass surgery: Pathophysiology, management, and future directions. Ann Surg 2013; 257(5): 824-33.
  4. Soverow J, Lee MS. Saphenous vein graft intervention: Status report 2014. J Invasive Cardiol 2014; 26(12): 659-67.
  5. Eid-Lidt G, Gaspar J, Adames AE, Damas de Los SF, Valdez R, I, Ramirez-Gutierrez AE, et al. Long-term outcomes of saphenous vein graft stenting compared with native coronary artery stenting in patients with previous coronary artery bypass graft surgery. Arch Cardiol Mex 2010; 80(1): 3-9.
  6. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: A review of mechanisms and therapies. Eur Heart J 2001; 22(9): 729-39.
  7. Jaffe R, Charron T, Puley G, Dick A, Strauss BH. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation 2008; 117(24): 3152-6.
  8. Niccoli G, Kharbanda RK, Crea F, Banning AP. No-reflow: Again prevention is better than treatment. Eur Heart J 2010; 31(20): 2449-55.
  9. Hong YJ, Jeong MH, Ahn Y, Kang JC, Mintz GS, Kim SW, et al. Intravascular ultrasound findings that are predictive of no reflow after percutaneous coronary intervention for saphenous vein graft disease. Am J Cardiol 2012; 109(11): 1576-81.
  10. Sdringola S, Assali AR, Ghani M, Moustapha A, Achour H, Yusuf SW, et al. Risk assessment of slow or no-reflow phenomenon in aortocoronary vein graft percutaneous intervention. Catheter Cardiovasc Interv 2001; 54(3): 318-24.
  11. Liu MW, Douglas JS Jr, Lembo NJ, King SB 3rd. Angiographic predictors of a rise in serum creatine kinase (distal embolization) after balloon angioplasty of saphenous vein coronary artery bypass grafts. Am J Cardiol 1993; 72(7): 514-7.
  12. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150(9): 604-12.
  13. Eeckhout E. Percutaneous Interventional Cardiovascular Medicine: The PCR-EAPCI Textbook. London, UK: Europa; 2012.
  14. The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. N Engl J Med 1985; 312(14): 932-6.
  15. Morishima I, Sone T, Mokuno S, Taga S, Shimauchi A, Oki Y, et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J 1995; 130(2): 239-43.
  16. Harrison RW, Aggarwal A, Ou FS, Klein LW, Rumsfeld JS, Roe MT, et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol 2013; 111(2): 178-84.
  17. Zhou H, He XY, Zhuang SW, Wang J, Lai Y, Qi WG, et al. Clinical and procedural predictors of no-reflow in patients with acute myocardial infarction after primary percutaneous coronary intervention. World J Emerg Med 2014; 5(2): 96-102.
  18. Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003; 41(1): 1-7.
  19. Dong-bao L, Qi H, Zhi L, Shan W, Wei-ying J. Predictors and long-term prognosis of angiographic slow/no-reflow phenomenon during emergency percutaneous coronary intervention for ST-elevated acute myocardial infarction. Clin Cardiol 2010; 33(12): E7-12.
  20. Dobrzycki S, Kozuch M, Kaminski K, Korecki J, Ostasz A, Podgrudna E, et al. High cholesterol in patients with ECG signs of no-reflow after myocardial infarction. Rocz Akad Med Bialymst 2003; 48: 118-22.
  21. Iwakura K, Ito H, Kawano S, Okamura A, Kurotobi T, Date M, et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J 2006; 27(5): 534-9.
  22. Hu T, Wang HC, Wang RT, Lv AL, Luan RH, Li CX, et al. Effect of chronic pretreatment of angiotensin-converting receptor blocker on no-reflow phenomenon in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Cardiovasc Ther 2013; 31(3): e7-e11.
  23. Shemirani H, Tafti FD, Amirpour A. Comparison of no-reflow phenomenon after percutaneous coronary intervention for acute myocardial infarction between smokers and nonsmokers. J Res Med Sci 2014; 19(11): 1068-73.
  24. Turkmen S, Dogdu O, Tekin K, Kucukdurmaz Z, Cagliyan CE, Sarikaya S, et al. The relationship between neutrophil/lymphocyte ratio and the TIMI flow grade in patients with STEMI undergoing primary PCI. Eur Rev Med Pharmacol Sci 2013; 17(16): 2185-9.
  25. Engler RL, Schmid-Schonbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol 1983; 111(1): 98-111.
  26. Brosh D, Assali AR, Mager A, Porter A, Hasdai D, Teplitsky I, et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol 2007; 99(4): 442-5.
  27. Kojima S, Sakamoto T, Ishihara M, Kimura K, Miyazaki S, Tei C, et al. The white blood cell count is an independent predictor of no-reflow and mortality following acute myocardial infarction in the coronary interventional era. Ann Med 2004; 36(2): 153-60.
  28. Akpek M, Kaya MG, Lam YY, Sahin O, Elcik D, Celik T, et al. Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol 2012; 110(5): 621-7.
  29. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002; 105(5): 656-62.
  30. Botto N, Sbrana S, Trianni G, Andreassi MG, Ravani M, Rizza A, et al. An increased platelet-leukocytes interaction at the culprit site of coronary artery occlusion in acute myocardial infarction: A pathogenic role for "no-reflow" phenomenon? Int J Cardiol 2007; 117(1): 123-30.
  31. Jinnouchi H, Sakakura K, Wada H, Arao K, Kubo N, Sugawara Y, et al. Transient no reflow following primary percutaneous coronary intervention. Heart Vessels 2014; 29(4): 429-36.
  32. Kurtul A, Murat SN, Yarlioglues M, Duran M, Celik IE, Kilic A. Mild to moderate renal impairment is associated with no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. Angiology 2015; 66(7): 644-51.
  33. Yilmaz MB, Yalta K. Coronary flow slows as renal function worsens. Clin Cardiol 2009; 32(5): 278-82.
  34. Hong YJ, Jeong MH, Choi YH, Ko JS, Lee MG, Kang WY, et al. Predictors of no-reflow after percutaneous coronary intervention for culprit lesion with plaque rupture in infarct-related artery in patients with acute myocardial infarction. J Cardiol 2009; 54(1): 36-44.
  35. Jiao Q, Ke Q, Li W, Jin M, Luo Y, Zhang L, et al. Effect of inflammatory factor-induced cyclo-oxygenase expression on the development of reperfusion-related no-reflow phenomenon in acute myocardial infarction. Clin Exp Pharmacol Physiol 2015; 42(2): 162-70.
  36. Ndrepepa G, Tiroch K, Keta D, Fusaro M, Seyfarth M, Pache J, et al. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv 2010; 3(1): 27-33.
  37. Orn S, Manhenke C, Ueland T, Damas JK, Mollnes TE, Edvardsen T, et al. C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. Eur Heart J 2009; 30(10): 1180-6.
  38. Hong YJ, Jeong MH, Choi YH, Ko JS, Lee MG, Kang WY, et al. Impact of plaque components on no-reflow phenomenon after stent deployment in patients with acute coronary syndrome: A virtual histology-intravascular ultrasound analysis. Eur Heart J 2011; 32(16): 2059-66.
  39. Antoniucci D, Valenti R, Migliorini A, Moschi G, Bolognese L, Cerisano G, et al. Direct infarct artery stenting without predilation and no-reflow in patients with acute myocardial infarction. Am Heart J 2001; 142(4): 684-90.
  40. Li C, Zhang B, Li M, Liu J, Wang L, Liu Y, et al. Comparing direct stenting with conventional stenting in patients with acute coronary syndromes: A meta-analysis of 12 clinical trials. Angiology 2016; 67(4): 317-25.
  41. Leborgne L, Cheneau E, Waksman R. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002; 106(15): e68.
  42. Cohen DJ, Murphy SA, Baim DS, Lavelle TA, Berezin RH, Cutlip DE, et al. Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: results from the SAFER trial. J Am Coll Cardiol 2004; 44(9): 1801-8.